Skip to main content

Advertisement

SpringerLink
Log in

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

The identification and validation of putative surrogate endpoints in oncology is a great challenge to medical investigators, statisticians, and regulators. A putative surrogate endpoint must be validated at both individual-level and trial-level before it can be used to replace the clinical endpoint in a future clinical trial. Recently, meta-analytic methods for evaluating potential surrogates have become widely accepted in cancer clinical trials. In this review, after addressing multiple complications and general issues surrounding surrogate endpoints, we review various proposed and adopted meta-analytic methodologies pertaining to the application of these methods to oncology clinical trials with different tumor types. In oncology, several applications have successfully identified useful surrogates. For example, disease-free survival and progression-free survival have been validated through meta-analyses as acceptable surrogates for overall survival in adjuvant colon cancer and advanced colorectal cancer, respectively. We also discuss several limitations of surrogate endpoints, including the critical issues that the extrapolation of the validity of a surrogate is always context-dependent and that such extrapolation should be exercised with caution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Johnson JR, Temple R (1985) Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155–1159

    PubMed  CAS  Google Scholar 

  2. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613

    PubMed  CAS  Google Scholar 

  3. Schatzkin A (2000) Intermediate markers as surrogate endpoints in cancer research. Hematol Oncol Clin North Am 14:887–905

    Article  PubMed  CAS  Google Scholar 

  4. Fleming TR (2005) Surrogate endpoints and FDA’s accelerated approval process. Health Aff (Millwood) 24:67–78

    Article  Google Scholar 

  5. Collette L, Burzykowski T, Schroder FH (2006) Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 42:1344–1350

    Article  PubMed  Google Scholar 

  6. Ellenberg S, Hamilton JM (1989) Surrogate endpoints in clinical trials: cancer. Stat Med 8:405–413

    Article  PubMed  CAS  Google Scholar 

  7. Herson J (1989) The use of surrogate endpoints in clinical trials (an introduction to a series of four papers). Stat Med 8:403–404

    Article  Google Scholar 

  8. Hillis A, Seigel D (1989) Surrogate endpoints in clinical trials: ophthalmologic disorders. Stat Med 8:427–430

    Article  PubMed  CAS  Google Scholar 

  9. Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431–440

    Article  PubMed  CAS  Google Scholar 

  10. Wittes J, Lakatos E, Probstfield J (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8:415–425

    Article  PubMed  CAS  Google Scholar 

  11. Boissel JP, Collet JP, Moleur P, et al (1992) Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 43: 235–244

    Article  PubMed  CAS  Google Scholar 

  12. Kosorok MR (1993) Using surrogate failure time data to increase cost effectiveness in clinical trials. Biometrika 80:823–833

    Article  Google Scholar 

  13. Fleming TR (1994) Surrogate markers in AIDS and cancer trials. Stat Med 13:1423–1435; discussion 1437–1440

    Article  PubMed  CAS  Google Scholar 

  14. Temple RJ (1995) A regulatory authority’s opinion about surrogate endpoints. In: Nimmo WS, Tucker GT (eds) Clinical measurement in drug evaluation. John Wiley and Sons, New York, pp 1–22

    Google Scholar 

  15. De Gruttola V, Fleming T, Lin DY, et al. (1997) Perspective: validating surrogate markers-are we being naive? J Infect Dis 175:237–246

    PubMed  Google Scholar 

  16. Lassere MN, Johnson KR, Boers M, et al. (2007) Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 34:607–615

    PubMed  Google Scholar 

  17. D’Agostino RB Jr (2000) Debate: the slippery slope of surrogate outcomes. Curr Control Trials Cardiovasc Med 1:76–78

    Article  PubMed  Google Scholar 

  18. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  19. Manns B, Owen WF Jr, Winkelmayer WC, et al. (2006) Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis 48:159–166

    Article  PubMed  Google Scholar 

  20. Gluud C, Brok J, Gong Y, et al. (2007) Hepatology may have problems with putative surrogate outcome measures. J Hepatol 46:734–742

    Article  PubMed  Google Scholar 

  21. US Department of Health and Human Services (2004) FDA: the nation’s premier consumer health protection agency. In: US Food and Drug Administration Washington, DC

    Google Scholar 

  22. US Department of Health and Human Services (2004) Guidance for industry: fast track drug development programs-designation, development, and application review. In: US Food and Drug Administration, Washington, DC

    Google Scholar 

  23. Katz R. (2004) Biomarkers and surrogate markers: an FDA perspective. NeuroRx®: J Am Soc Exp NeuroTher 1:189–195

    Google Scholar 

  24. Note for guidance on general considerations for clinical trials (CPMP/ICH/291/95). ICH Topic E 8: general considerations for clinical trials (2006)

  25. Freud S (1910) The origin and development of psychoanalysis. Am J Psychol 21:181–218

    Article  Google Scholar 

  26. Wood PH (1983) Where are we now with radiographic assessment of rheumatoid arthritis? Br J Rheumatol 22:24–33

    PubMed  CAS  Google Scholar 

  27. D’Agostino RB, Campbell MJ, Greenhouse JB (2006) Surrogate markers: back to the future. Stat Med 25:181–182

    Article  PubMed  Google Scholar 

  28. Ray K, Sarkar PK (1999) Surrogate endpoints: do they really contribute in therapeutic decision making? J Assoc Physicians India 47:894–896

    PubMed  CAS  Google Scholar 

  29. Johnston K (1999) What are surrogate outcome measures and why do they fail in clinical research? Neuroepidemiology 18: 167–173

    Article  PubMed  CAS  Google Scholar 

  30. Psaty BM, Weiss NS, Furberg CD, et al. (1999) Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 282:786–790

    Article  PubMed  CAS  Google Scholar 

  31. Grimes DA, Schulz KF (2005) Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 105: 1114–1118

    PubMed  Google Scholar 

  32. Hemila H (2007) Small trials focusing on surrogate end points may be uninformative. Eur J Appl Physiol 99:707–708

    Article  PubMed  Google Scholar 

  33. Hardman JG, Moppett IK, Mahajan RP (2008) Validity, credibility, and applicability: the rise and rise of the surrogate. Br J Anaesth 101:595–596

    Article  PubMed  CAS  Google Scholar 

  34. De Gruttola VG, Clax P, DeMets DL, et al. (2001) Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control Clin Trials 22:485–502

    Article  PubMed  Google Scholar 

  35. Baker SG, Kramer BS (2003) A perfect correlate does not a surrogate make. BMC Med Res Methodol 3:16

    Article  PubMed  Google Scholar 

  36. Lipicky RJ, Packer M (1993) Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 22: 179A–184A

    Article  PubMed  CAS  Google Scholar 

  37. Altman DG (1994) The scandal of poor medical research. BMJ 308:283–284

    PubMed  CAS  Google Scholar 

  38. Sobel BE, Furberg CD (1997) Surrogates, semantics, and sensible public policy. Circulation 95:1661–1663

    PubMed  CAS  Google Scholar 

  39. Ridker PM, Torres J (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000–2005. JAMA 295:2270–2274

    Article  PubMed  CAS  Google Scholar 

  40. Mansfield PR, Lexchin J, Wen LS, et al. (2006) Educating health professionals about drug and device promotion: advocates’ recommendations. PLoS Med 3:e451

    Article  PubMed  Google Scholar 

  41. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412

    Google Scholar 

  42. Weir CJ, Walley RJ (2006) Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 25:183–203

    Article  PubMed  Google Scholar 

  43. Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167–178

    Article  PubMed  CAS  Google Scholar 

  44. Lassere MN (2008) The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 17:303–340

    Article  PubMed  Google Scholar 

  45. Burzykowski T, Molenberghs G, Buyse M (eds) (2005) The evaluation of surrogate endpoints (statistics for biology and health). Springer, Berlin Heidelberg New York

    Google Scholar 

  46. Lin DY, Fleming TR, De Gruttola V (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16:1515–1527

    Article  PubMed  CAS  Google Scholar 

  47. Buyse M, Molenberghs G (1998) Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014–1029

    Article  PubMed  CAS  Google Scholar 

  48. Molenberghs G, Buyse M, Geys H, et al. (2002) Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 23:607–625

    Article  PubMed  Google Scholar 

  49. Bycott PW, Taylor JM (1998) An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker. Control Clin Trials 19:555–568

    Article  PubMed  CAS  Google Scholar 

  50. Flandre P, Saidi Y (1999) Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 18:107–109

    Article  PubMed  CAS  Google Scholar 

  51. Buyse M, Molenberghs G, Burzykowski T, et al. (2000) Statistical validation of surrogate endpoints: problems and proposals. Drug Inf J 34:447–454

    Google Scholar 

  52. Molenberghs G, Burzykowski T, Alonso A, et al. (2004) A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 13:177–206

    PubMed  Google Scholar 

  53. Lassere M, Johnson K, Hughes M, et al. (2007) Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches. J Rheumatol 34:616–619

    PubMed  Google Scholar 

  54. Buyse M, Molenberghs G, Burzykowski T, et al. (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49–67

    Article  PubMed  Google Scholar 

  55. Alonso A, Molenberghs G, Burzykowski T, et al. (2004) Prentice’s approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 60:724–728

    Article  PubMed  Google Scholar 

  56. Hughes MD (2002) Evaluating surrogate endpoints. Control Clin Trials 23:703–707

    Article  PubMed  Google Scholar 

  57. Hughes MD, DeGruttola V, Welles SL (1995) Evaluating surrogate markers. J Acquir Immune Defic Syndr Hum Retrovirol 10(Suppl 2):S1–8

    PubMed  Google Scholar 

  58. Daniels MJ, Hughes MD (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16:1965–1982

    Article  PubMed  CAS  Google Scholar 

  59. Gail MH, Pfeiffer R, Van Houwelingen HC, et al. (2000) On meta-analytic assessment of surrogate outcomes. Biostatistics 1:231–246

    Article  PubMed  CAS  Google Scholar 

  60. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and metaregression. Stat Med 21:589–624

    Article  PubMed  Google Scholar 

  61. Alonso A, Molenberghs G (2007) Surrogate marker evaluation from an information theory perspective. Biometrics 63:180–186

    Article  PubMed  Google Scholar 

  62. Tilahun A, Pryseley A, Alonso A, et al. (2008) Information theory-based surrogate marker evaluation from several randomized clinical trials with binary endpoints, using SAS. J Biopharm Stat 18:326–341

    Article  PubMed  Google Scholar 

  63. Alonso A, Molenberghs G (2008) Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Stat Methods Med Res 17:497–504

    Article  PubMed  Google Scholar 

  64. Pryseley A, Tilahun A, Alonso A, et al. (2007) Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints. Clin Trials 4:587–597

    Article  PubMed  Google Scholar 

  65. Sargent DJ, Wieand HS, Haller DG, et al. (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670

    Article  PubMed  Google Scholar 

  66. Sargent DJ, Patiyil S, Yothers G, et al. (2007) End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20 898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25:4569–4574

    Article  PubMed  Google Scholar 

  67. Baker SG (2006) A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint. Biostatistics 7:58–70

    Article  PubMed  Google Scholar 

  68. Baker SG (2008) Two simple approaches for validating a binary surrogate endpoint using data from multiple trials. Stat Methods Med Res 17:505–514

    Article  PubMed  Google Scholar 

  69. Korn EL, Albert PS, McShane LM (2005) Assessing surrogates as trial endpoints using mixed models. Stat Med 24:163–182

    Article  PubMed  Google Scholar 

  70. Abrahantes JC, Shkedy Z, Molenberghs G (2008) Alternative methods to evaluate trial level surrogacy. Clin Trials 5:194–208

    Article  PubMed  Google Scholar 

  71. Burzykowski T, Buyse M (2006) Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 5:173–186

    Article  PubMed  Google Scholar 

  72. Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411

    Article  PubMed  Google Scholar 

  73. Dagher R, Johnson J, Williams G, et al. (2004) Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst 96:1500–1509

    PubMed  Google Scholar 

  74. Buyse M, Thirion P, Carlson RW, et al. (2000) Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 356:373–378

    Article  PubMed  CAS  Google Scholar 

  75. Tang PA, Bentzen SM, Chen EX, et al. (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562–4568

    Article  PubMed  Google Scholar 

  76. Hackshaw A, Knight A, Barrett-Lee P, et al. (2005) Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 93:1215–1221

    Article  PubMed  CAS  Google Scholar 

  77. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987–1992

    Article  PubMed  CAS  Google Scholar 

  78. Burzykowski T, Buyse M, Yothers G, et al. (2008) Exploring and validating surrogate endpoints in colorectal cancer. Lifetime Data Anal 14:54–64

    Article  PubMed  Google Scholar 

  79. Buyse M, Burzykowski T, Carroll K, et al. (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218–5224

    Article  PubMed  CAS  Google Scholar 

  80. Miksad RA, Zietemann V, Gothe R, et al. (2008) Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 24:371–383

    Article  PubMed  Google Scholar 

  81. Roessner M, De Wit R, Tannock IF (2005) Prostate-specific antigen (PSA) response as surrogate endpoint for overall survival (OS): analysis of the TAX 327 Study comparing docetaxel plus prednisone to mitoxantrone plus prednisone in advanced prostate cancer (abstract). J Clin Oncol 23:391s

    Google Scholar 

  82. Chakravarty A, Sridhara R (2008) Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 17:515–518

    Article  PubMed  Google Scholar 

  83. Hughes MD (2008) Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer. Stat Methods Med Res 17:487–495

    Article  PubMed  Google Scholar 

  84. Powers JH (2005) Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. Pharmacotherapy 25:109S–123S

    Article  PubMed  Google Scholar 

  85. Punt CJ, Buyse M, Kohne CH, et al. (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 99:998–1003

    Article  PubMed  Google Scholar 

  86. Stewart LA, Clarke MJ (1995) Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Stat Med 14:2057–2079

    CAS  Google Scholar 

  87. Packer M, Carver JR, Rodeheffer RJ, et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468–1475

    PubMed  CAS  Google Scholar 

  88. Packers M, Rouleau J, Swedberg K, et al. (1993) Effect of Flosequinan on survival in chronic heart failure: Preliminary results of the PROFILE study (abstract). Circulation 88:I–301

    Google Scholar 

  89. Califf RM, Adams KF, McKenna WJ, et al. (1997) A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134:44–54

    Article  PubMed  CAS  Google Scholar 

  90. Hulley S, Grady D, Bush T, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  91. Rossouw JE, Anderson GL, Prentice RL, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  92. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199–208

    Article  Google Scholar 

  93. Report of the Committee of Principal Investigators (1980) W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 2:379–385

    Google Scholar 

  94. Gordon DJ (1994) Cholesterol lowering and total mortality. In: Contemporary issues in cholesterol lowering: clinical and population aspects. Marcel Dekker, New York

    Google Scholar 

  95. Riggs BL, Hodgson SF, O’Fallon WM, et al. (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–8029

    PubMed  CAS  Google Scholar 

  96. Aboulker JP, Swart AM, Committee CC (1993) Preliminary analysis of the Concorde trial. Lancet 341:889–890

    Article  PubMed  CAS  Google Scholar 

  97. Baker SG, Izmirlian G, Kipnis V (2005) Resolving paradoxes involving surrogate end points. J R Stat Soc Ser A Stat Soc 168:753–762

    Article  Google Scholar 

  98. Renard D, Geys H, Molenberghs G, et al. (2002) Validation of surrogate endpoints in multiple randomized clinical trials with discrete outcomes. Biom J 44:921–935

    Article  Google Scholar 

  99. Molenberghs G, Geys H, Buyse M (2001) Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes. Stat Med 20:3023–3038

    Article  PubMed  CAS  Google Scholar 

  100. Burzykowski T, Molenberghs G, Buyse M (2004) The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. J R Stat Soc Ser A Stat Soc 167:103–124

    Article  Google Scholar 

  101. Burzykowski T, Molenberghs G, Buyse M, et al. (2001) Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J Appl Stat 50:405–422

    Google Scholar 

  102. Renard D, Geys H, Molenberghs G, et al. (2002) Validation of longitudinally measured surrogate marker for a time-to-event endpoint. J Appl Stat 30:235–247

    Google Scholar 

  103. Buyse M, Vangeneugden T, Bijnens L, et al. (2003) Validation of biomarkers as surrogates for clinical endpoints. Marcel Dekker, New York

    Google Scholar 

  104. Newling D, Carroll K, Morris T (2004) Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer? (abstract) J Clin Oncol 22:4652

    Article  Google Scholar 

  105. Collette L, Burzykowski T, Carroll KJ, et al. (2005) Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23:6139–6148

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA

    Qian Shi & Daniel J. Sargent

Authors
  1. Qian Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel J. Sargent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qian Shi.

About this article

Cite this article

Shi, Q., Sargent, D.J. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 14, 102–111 (2009). https://doi.org/10.1007/s10147-009-0885-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-009-0885-4

Key words

Search

Navigation